- Home
- IPHA vs RMNI Comparison
IPHA vs RMNI Comparison
Compare IPHA & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | RMNI |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 372.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | IPHA | RMNI |
|---|---|---|
| Price | $1.71 | $3.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.00 | ★ $5.50 |
| AVG Volume (30 Days) | 26.6K | ★ 280.4K |
| Earning Date | 09-17-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $14,839,695.00 | ★ $425,959,000.00 |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | $3.13 |
| P/E Ratio | ★ N/A | $8.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $2.49 |
| 52 Week High | $2.63 | $5.38 |
Technical Indicators
Market Signals| Indicator | IPHA | RMNI |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 48.25 |
| Support Level | $1.64 | $3.93 |
| Resistance Level | $1.81 | $4.08 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 18.75 | 28.57 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About RMNI Rimini Street Inc. (DE)
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The Company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, database, and technology software platforms. The Company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management database, and technology software systems. Geographically, the company generates the majority of its revenue from the United States of America and the International market.